Clinical trial

A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT)

NCT02637856

Drugs and interventions used in this trial

2 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Mapped RxNorm record Ocrelizumab Normalized identity: ocrelizumabView linked drug · Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT)

Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE3

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2016-02-11

PhasePHASE3

Conditions

Multiple Sclerosis, Relapsing-Remittingunresolved

Interventions

OcrelizumabDRUG · verified · RxNorm: ocrelizumab

Sponsors & collaborators

Genentech, Inc.lead sponsor

Mapped research locations

BostonMassachusetts, United States2 BaltimoreMaryland, United States2 TampaFlorida, United States2 MontrealQuebec, Canada2 PhoenixArizona, United States2 LexingtonKentucky, United States2 New YorkNew York, United States1 HoustonTexas, United States1 ChicagoIllinois, United States1 St LouisMissouri, United States1 AtlantaGeorgia, United States1 MiamiFlorida, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT02637856 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.